Core Viewpoint - The stock of Deqi Pharmaceutical-B (06996) rose over 6% following the announcement of positive clinical trial results for its ADC ATG-022 at the ESMO 2025 conference, indicating strong safety and anti-tumor activity across various patient groups [1] Group 1: Clinical Research Results - Deqi Pharmaceutical presented the latest findings from the I/II phase clinical study of ATG-022, an antibody-drug conjugate targeting CLDN18.2, at the ESMO 2025 conference in Berlin [1] - ATG-022 demonstrated good safety and significant anti-tumor activity in patients with gastric cancer (GC) and gastroesophageal junction cancer (GEJC) across different levels of CLDN18.2 expression [1] - Preliminary efficacy was also observed in other non-gastrointestinal tumors, with further data expected to be presented at upcoming academic meetings [1] Group 2: Dosage and Safety Data - The safety data for the 2.4 mg/kg dosage group was reported to be good, while the 1.8 mg/kg dosage group showed even better safety and tolerability [1] - These findings support the potential for ATG-022 to be combined with immune checkpoint inhibitors and chemotherapy in frontline treatment, significantly expanding its clinical applicability and commercialization potential [1] Group 3: Ongoing Development - The I phase dose expansion study of ATG-022 is progressing smoothly in mainland China and Australia [1] - The company is actively preparing for clinical research on combination therapies involving ATG-022 to further advance its clinical development process [1]
德琪医药-B涨超6% 公布ATG-022的I/II期临床研究最新研究成果